Rite Aid

Rite Aid is a pharmacy retail healthcare company. The company's Retail Pharmacy segment sells brand and generic prescription drugs, as well as an assortment of front-end products including health and beauty aids, personal care products, seasonal merchandise, and a private brand product line. The company's Pharmacy Services segment provides pharmacy benefit management (PBM) options through its EnvisionRxOptions and MedTrak PBMs, respectively. EnvisionRxOptions also provides mail-order and specialty pharmacy services through EnvisionPharmacies; a claims adjudication software platform in Laker Software; and a national Medicare Part D prescription drug plan through its EnvisionRx Plus product offering.
  • TickerRAD
  • ISINUS7677548726
  • ExchangeNew York Stock Exchange
  • SectorFood & Drug Retailers
  • CountryUnited States
RAD RITE AID (Retail)

Thanks to a better fundamental star rating, RITE AID sees an upgrade t...

The independent financial analyst theScreener just awarded an improved star rating to RITE AID (US), active in the Drug Retailers industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 4 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date June 15, 2021, the closing price was USD 22.05 and its expected value was estimated at USD 19.97.

RAD RITE AID (Retail)

Moody's changes Rite Aid's outlook to positive; affirms Caa1 CFR

Rating Action: Moody's changes Rite Aid's outlook to positive; affirms Caa1 CFR. Global Credit Research- 13 May 2021. New York, May 13, 2021-- Moody's Investors Service, today changed the outlook for Rite Aid Corporation to positive from stable.

RAD RITE AID (Retail)

Moody's announces completion of a periodic review of ratings of Rite A...

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Rite Aid Corporation. Global Credit Research- 23 Mar 2021. New York, March 23, 2021-- Moody's Investors Service has completed a periodic review of the ratings of Rite Aid Corporation and other ratings that are associated with the same analytical unit.

Valens Research
  • Valens Research
RAD RITE AID (Retail)

RAD - Embedded Expectations Analysis - 2021 02 24

Rite Aid Corporation (RAD:USA) currently trades above corporate averages relative to UAFRS-based (Uniform) earnings, with a 24.3x Uniform P/E. At these levels, the market has bullish expectations for the firm, but management may have concerns about their omnichannel capabilities, store remodeling costs, and weak flu and cold volumes Specifically, management may lack confidence in their ability to mitigate drug cost-driven adjusted EBITDA declines, sustain retail pharmacy market share gains, and grow their specialty pharmacy business. Furthermore, they may be exaggerating the long-term potenti...

RAD RITE AID (Retail)

Rite Aid Corporation - November 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers

RAD RITE AID (Retail)

Thanks to a better fundamental star rating, RITE AID sees an upgrade t...

The independent financial analyst theScreener just awarded an improved star rating to RITE AID (US), active in the Drug Retailers industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 4 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date June 15, 2021, the closing price was USD 22.05 and its expected value was estimated at USD 19.97.

RAD RITE AID (Retail)

Moody's changes Rite Aid's outlook to positive; affirms Caa1 CFR

Rating Action: Moody's changes Rite Aid's outlook to positive; affirms Caa1 CFR. Global Credit Research- 13 May 2021. New York, May 13, 2021-- Moody's Investors Service, today changed the outlook for Rite Aid Corporation to positive from stable.

RAD RITE AID (Retail)

Moody's announces completion of a periodic review of ratings of Rite A...

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Rite Aid Corporation. Global Credit Research- 23 Mar 2021. New York, March 23, 2021-- Moody's Investors Service has completed a periodic review of the ratings of Rite Aid Corporation and other ratings that are associated with the same analytical unit.

Valens Research
  • Valens Research
RAD RITE AID (Retail)

RAD - Embedded Expectations Analysis - 2021 02 24

Rite Aid Corporation (RAD:USA) currently trades above corporate averages relative to UAFRS-based (Uniform) earnings, with a 24.3x Uniform P/E. At these levels, the market has bullish expectations for the firm, but management may have concerns about their omnichannel capabilities, store remodeling costs, and weak flu and cold volumes Specifically, management may lack confidence in their ability to mitigate drug cost-driven adjusted EBITDA declines, sustain retail pharmacy market share gains, and grow their specialty pharmacy business. Furthermore, they may be exaggerating the long-term potenti...

RAD RITE AID (Retail)

Rite Aid Corporation - November 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers

RAD RITE AID (Retail)

Thanks to a better fundamental star rating, RITE AID sees an upgrade t...

The independent financial analyst theScreener just awarded an improved star rating to RITE AID (US), active in the Drug Retailers industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 4 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date June 15, 2021, the closing price was USD 22.05 and its expected value was estimated at USD 19.97.

RAD RITE AID (Retail)

Moody's changes Rite Aid's outlook to positive; affirms Caa1 CFR

Rating Action: Moody's changes Rite Aid's outlook to positive; affirms Caa1 CFR. Global Credit Research- 13 May 2021. New York, May 13, 2021-- Moody's Investors Service, today changed the outlook for Rite Aid Corporation to positive from stable.

RAD RITE AID (Retail)

Moody's announces completion of a periodic review of ratings of Rite A...

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Rite Aid Corporation. Global Credit Research- 23 Mar 2021. New York, March 23, 2021-- Moody's Investors Service has completed a periodic review of the ratings of Rite Aid Corporation and other ratings that are associated with the same analytical unit.

Valens Research
  • Valens Research
RAD RITE AID (Retail)

RAD - Embedded Expectations Analysis - 2021 02 24

Rite Aid Corporation (RAD:USA) currently trades above corporate averages relative to UAFRS-based (Uniform) earnings, with a 24.3x Uniform P/E. At these levels, the market has bullish expectations for the firm, but management may have concerns about their omnichannel capabilities, store remodeling costs, and weak flu and cold volumes Specifically, management may lack confidence in their ability to mitigate drug cost-driven adjusted EBITDA declines, sustain retail pharmacy market share gains, and grow their specialty pharmacy business. Furthermore, they may be exaggerating the long-term potenti...

RAD RITE AID (Retail)

Rite Aid Corporation - November 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers

RAD RITE AID (Retail)

Thanks to a better fundamental star rating, RITE AID sees an upgrade t...

The independent financial analyst theScreener just awarded an improved star rating to RITE AID (US), active in the Drug Retailers industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 4 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date June 15, 2021, the closing price was USD 22.05 and its expected value was estimated at USD 19.97.

RAD RITE AID (Retail)

Moody's changes Rite Aid's outlook to positive; affirms Caa1 CFR

Rating Action: Moody's changes Rite Aid's outlook to positive; affirms Caa1 CFR. Global Credit Research- 13 May 2021. New York, May 13, 2021-- Moody's Investors Service, today changed the outlook for Rite Aid Corporation to positive from stable.

RAD RITE AID (Retail)

Moody's announces completion of a periodic review of ratings of Rite A...

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Rite Aid Corporation. Global Credit Research- 23 Mar 2021. New York, March 23, 2021-- Moody's Investors Service has completed a periodic review of the ratings of Rite Aid Corporation and other ratings that are associated with the same analytical unit.

Valens Research
  • Valens Research
RAD RITE AID (Retail)

RAD - Embedded Expectations Analysis - 2021 02 24

Rite Aid Corporation (RAD:USA) currently trades above corporate averages relative to UAFRS-based (Uniform) earnings, with a 24.3x Uniform P/E. At these levels, the market has bullish expectations for the firm, but management may have concerns about their omnichannel capabilities, store remodeling costs, and weak flu and cold volumes Specifically, management may lack confidence in their ability to mitigate drug cost-driven adjusted EBITDA declines, sustain retail pharmacy market share gains, and grow their specialty pharmacy business. Furthermore, they may be exaggerating the long-term potenti...

RAD RITE AID (Retail)

Rite Aid Corporation - November 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers

RAD RITE AID (Retail)

Thanks to a better fundamental star rating, RITE AID sees an upgrade t...

The independent financial analyst theScreener just awarded an improved star rating to RITE AID (US), active in the Drug Retailers industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 4 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date June 15, 2021, the closing price was USD 22.05 and its expected value was estimated at USD 19.97.

RAD RITE AID (Retail)

Moody's changes Rite Aid's outlook to positive; affirms Caa1 CFR

Rating Action: Moody's changes Rite Aid's outlook to positive; affirms Caa1 CFR. Global Credit Research- 13 May 2021. New York, May 13, 2021-- Moody's Investors Service, today changed the outlook for Rite Aid Corporation to positive from stable.

RAD RITE AID (Retail)

Moody's announces completion of a periodic review of ratings of Rite A...

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Rite Aid Corporation. Global Credit Research- 23 Mar 2021. New York, March 23, 2021-- Moody's Investors Service has completed a periodic review of the ratings of Rite Aid Corporation and other ratings that are associated with the same analytical unit.

Valens Research
  • Valens Research
RAD RITE AID (Retail)

RAD - Embedded Expectations Analysis - 2021 02 24

Rite Aid Corporation (RAD:USA) currently trades above corporate averages relative to UAFRS-based (Uniform) earnings, with a 24.3x Uniform P/E. At these levels, the market has bullish expectations for the firm, but management may have concerns about their omnichannel capabilities, store remodeling costs, and weak flu and cold volumes Specifically, management may lack confidence in their ability to mitigate drug cost-driven adjusted EBITDA declines, sustain retail pharmacy market share gains, and grow their specialty pharmacy business. Furthermore, they may be exaggerating the long-term potenti...

RAD RITE AID (Retail)

Rite Aid Corporation - November 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers

ResearchPool Subscriptions

Get the most out of your insights

Get in touch